Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05264714
Other study ID # 21-003394
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date September 7, 2022
Est. completion date December 2024

Study information

Verified date March 2024
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research is to explore the efficacy of rimegepant as a preventative therapy for cluster headache.


Description:

This is a prospective, open-label pilot study to investigate the use of rimegepant for the treatment of cluster headache. Subjects will be screened at outpatient clinic visit appointments and interested qualified subjects will be consented and offered participation in this trial. Once consent has been obtained, patients with cluster headache will start immediately keeping track of their headaches for a one-week baseline. In contrast, patients with episodic cluster headache will be asked to contact the study coordinator at the onset of their next cluster cycle, at which point they will repeat the screening and then start their one-week baseline headache diary. After establishing the baseline headache frequency, severity, and abortive medicine use, patients will be asked to start their first dose of study drug with their next moderate to severe cluster headache. They will rate their pain for this headache on a 5 point severity scale ("no headache," "mild," "moderate," "severe" or "very severe" and rate the pain on a scale of 0 to 10 ("0" is no pain and "10" is most severe pain imaginable) at the time of taking rimegepant and rate the pain again at 15, 30, 45, and 60 minutes after taking the drug. 60 or more minutes after taking the rimegepant, they are allowed to use their usual standard of care for the acute/abortive treatment of acute cluster attacks. After this first dose, they will then take rimegepant on an every other day schedule for a total of 4 doses over 8 days. A final visit for evaluation and collection of headache diaries will be conducted at the end of the study.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Having a diagnosis of recurrent cluster headaches, as described by ICHD-3 (International Classification of Headache Disorders-3): - Severe or very severe unilateral orbital, supraorbital and/or temporal pain lasting 15-180 minutes, when untreated. - Headache is accompanied by at least one of the following: - Ipsilateral conjunctival injection and/or lacrimation; - Ipsilateral nasal congestion and/or rhinorrhea; - Ipsilateral eyelid edema; - Ipsilateral forehead and facial sweating; - Ipsilateral miosis and/or ptosis; - A sense of restlessness or agitation. - Headache attacks occur at a frequency between every other day and 8 per day. - Headaches are not attributed to another disorder. - Subjects able to distinguish cluster headache attacks from other headache disorders, such as migraine. - Subjects on prophylactic headache medicines other than verapamil will be permitted to remain on these with possible headache-prophylactic effects if the dose is stable for at least 2 months (onabotulinumtoxinA injections stable for 6 months) prior to the screening visit and the dose is not expected to change during the course of the study. - Prior MR (magnetic resonance) imaging of head (CT if MRI contraindicated) performed after the onset of headaches. - Subjects agree to refrain from starting a new prophylactic cluster headache medicine, including steroids and nerve blocks, during the course of the study. - Subjects are required to have a cluster headache attack fre-quency ranging from one attack every other day to eight attacks per day, with at least four total attacks during the one-week prospective baseline period. Additionally, episodic cluster headache patients are required to have a history of cluster head-ache period lasting at least 6 weeks. Exclusion Criteria: - Subjects with a history of an adverse reaction to CGRP (calcitonin gene-related peptide) antibodies or another CGRP antagonist (gepant). - Subjects with episodic cluster who are felt to be toward the end of their cluster cycle (estimated to be within the last 4 weeks). - Pregnancy (negative serum pregnancy testing at enrollment and use of contraception considered to be effective). - Subjects with a history of uncontrolled, unstable, or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Subjects with myocardial infarction (MI), percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), stroke, or transient ischemic attack (TIA) in the 6 months prior to screening. - Subjects with other pain syndromes, psychiatric conditions, dementia or significant neurological disorders that, in the investigator's opinion might interfere with study assessments. - Use of peripheral nerve blocks (e.g., occipital, supraorbital, auriculotemporal, and/or sphenopalatine ganglion nerve blocks) one month prior to enrollment. - Use of opioids or barbiturates more than 5 days per month. - Use of other small molecule CGRP antagonist (gepant) 1 month prior to enrollment or during duration of study - Use of verapamil during the study - Use of CGRP monoclonal antibodies 3 months prior to enrollment or during duration of study. - Subjects with a secondary cluster headache related to an underlying structural etiology identified by imaging (CT or MRI).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Rimegepant
150 mg oral disintegrating tablet every other day for one week

Locations

Country Name City State
United States Mayo Clinic Rochester Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in weekly frequency of cluster headache attacks Total number of cluster headache attacks experienced in one week Baseline, week of treatment (days 1-7)
Secondary Change in daily headache severity Change from baseline daily headache severity in days 1 through 8 in subjects treated with rimegepant, as measured on a Numeric Pain Rating Scale (NPRS), an 11-point scale from 0 to 10, where "0" indicates no pain and "10" suggests the most severe pain imaginable Baseline, week of treatment (days 1-8)
Secondary Change in daily frequency of cluster headache attacks Total number of cluster headaches experienced daily Baseline, week of treatment (days 1-8)
See also
  Status Clinical Trial Phase
Completed NCT01677026 - Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache
Terminated NCT00203190 - A Double-Blind, Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache Phase 4
Terminated NCT04570475 - High Dose Vitamin D Plus Multivitamin in the Prevention of Cluster Headache Phase 3
Completed NCT04066023 - Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches Phase 2/Phase 3
Withdrawn NCT04353505 - Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache Phase 1
Completed NCT02019017 - Botox Injection in Treatment of Cluster Headache Phase 1/Phase 2
Completed NCT05153876 - An Open Internet-based Survey and Natural Language Processing Project Analysing Written Monologues by Headache Patients
Recruiting NCT05324748 - Repeated GON Injections in CCH Phase 3
Completed NCT02782533 - DBS of the Third Ventricle for Cluster Headache and Obesity N/A
Completed NCT04179266 - Effect of Ketamine Intranasal Spray in Treatment of Chronic Cluster Headache Phase 1/Phase 2
Recruiting NCT04406259 - Atrioventricular Block and Cluster Headache (SEVA) Phase 4
Recruiting NCT06206772 - Resting State Functional Connectivity in Cluster Headache
Recruiting NCT03944876 - Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache Phase 3
Not yet recruiting NCT05857098 - Detection of Local Field Potentials in the Ventral Tegmental Area of the Midbrain in Chronic Cluster Headache Patients
Recruiting NCT02910323 - The Will Erwin Headache Research Center - Cluster Headache Study
Terminated NCT00458770 - Study of Hypothalamic Metabolism in Spontaneous Cluster Headache Attacks N/A
Completed NCT00662935 - Evaluation of Efficacity and Safety of Deep Brain Stimulation (DBS) in Chronic and Treatment-Resistant Cluster Headache(CH) N/A
Active, not recruiting NCT03511846 - Pain Biomarker Study Phase 1
Completed NCT00184587 - Prophylactic Treatment of Episodic Cluster Headache Phase 2
Not yet recruiting NCT06277063 - nVNS for the Prevention and Treatment of Primary Headache N/A